EBOLA: VANDERBILT UNIVERSITY JOINS IN THE EFFORT TO SPEED THE DEVELOPMENT OF POTENTIAL EBOLA THERAPIES

Vanderbilt University, Nashville, Tennessee researchers have joined a multicenter effort to speed up the development of potential antibody therapies against Ebola virus.

Vanderbilt University's James Crowe Jr. MD and his colleagues will provide human monoclonal antibodies they have generated against Ebola virus to Pensylvania based Inovio pharmaceuticals for further development.

The team from Vanderbilt University is expected to test the potential treatments for safety and efficacy in clinical trials.

Inovio Pharmaceuticals announced on Wednesday that it had been awarded an initial two year $21 million grant from Defence Advanced Research Projects Agency (DARPA).

 Vanderbilt's share of the grant is $1.3million.